Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 9 |
Bispecific T-cell Engager (BiTE) | 3 |
Bispecific antibody | 2 |
siRNA | 2 |
Antibody drug conjugate (ADC) | 2 |
Target |
Mechanism IL-4Rα inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date10 Sep 2024 |
Target |
Mechanism CLDN18.2 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD38 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Nov 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Start Date30 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Stapokibart ( IL-4Rα ) | Chronic rhinosinusitis with nasal polyps More | Approved |
CM-350 ( CD3 x GPC3 ) | Advanced Malignant Solid Neoplasm More | Phase 2 Clinical |
CM-338 ( MASP2 ) | Glomerulonephritis, IGA More | Phase 2 |
Lumrotatug ( CD38 ) | Systemic Lupus Erythematosus More | Phase 2 |
CM-326 ( TSLP ) | Asthma More | Phase 2 |